Evy Lundgren-Åkerlund active positions
| Companies | Position | Start | End |
|---|---|---|---|
| XINTELA AB | Chief Administrative Officer | - | - |
| Chief Executive Officer | 2009-03-31 | - | |
| Founder | 2008-12-31 | - | |
| Investor Relations Contact | - | - | |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Director/Board Member | - | - |
Career history of Evy Lundgren-Åkerlund
Former positions of Evy Lundgren-Åkerlund
| Companies | Position | Start | End |
|---|---|---|---|
| Lund Life Science Incubator | Chief Executive Officer | 2007-12-31 | 2011-12-31 |
| Chief Operating Officer | 2007-12-31 | 2011-12-31 | |
Cartela AB
 Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Chief Tech/Sci/R&D Officer | 2000-08-31 | 2008-12-23 |
| Founder | 2000-08-31 | 2008-12-23 |
Statistics
International
| Sweden | 5 |
Operational
| Founder | 2 |
| Chief Executive Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Private companies | 3 |
|---|---|
Cartela AB
Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Health Technology |
| Lund Life Science Incubator | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
